Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT01572909
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Stealth BioTherapeutics Inc.
- Registry
-
NCT01572909
-
- Other papers using this trial's data
- Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Hungary, Poland
- Registry status
- Completed
Technical summary
Registry record NCT01572909. Randomized; triple masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2020-06-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
- Acronym
- EMBRACE
- Condition
- Reperfusion Injury
- Condition
- STEMI
- Intervention (Drug)
- Bendavia (MTP-131)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Collaborator
- ICON Clinical Research
Record details
- Record id
cardio:ct-nct01572909- Content hash
ac1c7ffcd6a62b614ccd161e45f3b5b6119661812ca1769a2d68414f19aa0d0a